Analysts Set Prestige Consumer Healthcare Inc. (NYSE:PBH) PT at $70.75

Prestige Consumer Healthcare Inc. (NYSE:PBH) has been assigned an average rating of “Hold” from the six analysts that are covering the company, MarketBeat.com reports. One analyst has rated the stock with a sell rating, three have issued a hold rating and two have issued a buy rating on the company. The average 1 year price objective among brokerages that have issued ratings on the stock in the last year is $70.75.

PBH has been the subject of several research reports. Weiss Ratings cut shares of Prestige Consumer Healthcare from a “hold (c-)” rating to a “sell (d+)” rating in a report on Thursday, June 25th. Zacks Research upgraded shares of Prestige Consumer Healthcare from a “strong sell” rating to a “hold” rating in a report on Monday, August 10th.

Prestige Consumer Healthcare Trading Up 1.9%

Prestige Consumer Healthcare stock opened at $47.70 on Friday. Prestige Consumer Healthcare has a one year low of $42.62 and a one year high of $71.07. The business’s fifty day moving average is $50.53 and its 200 day moving average is $52.26. The stock has a market capitalization of $2.26 billion, a PE ratio of 13.36, a price-to-earnings-growth ratio of 1.47 and a beta of 0.33. The company has a debt-to-equity ratio of 1.06, a current ratio of 3.23 and a quick ratio of 1.99.

Prestige Consumer Healthcare (NYSE:PBH) last issued its earnings results on Thursday, August 6th. The company reported $0.98 earnings per share for the quarter, topping analysts’ consensus estimates of $0.89 by $0.09. The business had revenue of $265.71 million during the quarter, compared to analyst estimates of $253.02 million. Prestige Consumer Healthcare had a return on equity of 11.39% and a net margin of 15.57%.Prestige Consumer Healthcare’s revenue was up 6.5% on a year-over-year basis. During the same quarter in the previous year, the firm earned $0.90 EPS. Prestige Consumer Healthcare has set its FY 2027 guidance at 4.550-4.650 EPS. On average, sell-side analysts predict that Prestige Consumer Healthcare will post 4.56 EPS for the current year.

Hedge Funds Weigh In On Prestige Consumer Healthcare

Hedge funds and other institutional investors have recently modified their holdings of the company. BlackRock Inc. purchased a new position in shares of Prestige Consumer Healthcare in the 2nd quarter worth $370,187,000. Dimensional Fund Advisors LP increased its position in Prestige Consumer Healthcare by 3.6% during the first quarter. Dimensional Fund Advisors LP now owns 2,672,777 shares of the company’s stock valued at $158,414,000 after acquiring an additional 91,710 shares during the last quarter. Rice Hall James & Associates LLC bought a new position in Prestige Consumer Healthcare in the second quarter valued at about $32,602,000. The Manufacturers Life Insurance Company bought a new position in Prestige Consumer Healthcare in the second quarter valued at about $31,135,000. Finally, Brandes Investment Partners LP boosted its position in Prestige Consumer Healthcare by 93.2% in the fourth quarter. Brandes Investment Partners LP now owns 606,737 shares of the company’s stock worth $37,430,000 after purchasing an additional 292,744 shares during the last quarter. 99.95% of the stock is owned by institutional investors.

About Prestige Consumer Healthcare

Prestige Consumer Healthcare Inc (NYSE: PBH) develops, markets and distributes over-the-counter health care products and household consumer products. Its portfolio includes branded treatments for eye care, gastrointestinal health, women’s health, oral care, respiratory conditions, pain relief and skin care, along with products for lice treatment and motion sickness.

The company’s brands include Clear Eyes, Dramamine, Monistat, Summer’s Eve, Compound W, Chloraseptic, Luden’s, BC, Goody’s, Nix and Hydralyte, among others.